Every year, millions of people are diagnosed with cancer globally; however, current treatments are limited by disease complexity. A study published in the open-access journal in PLOS Biology by Tianyu Jiang at Shandong University, Qingdao, China and colleagues suggests that Escherichia coli Nissle 1917 (EcN) may be engineered with anticancer agents to treat cancerous tumors in mice.
This article was originally published on MedicalXpress.com

